Results 111 to 120 of about 2,276,667 (238)
Slc44a2 Deficiency Unveils an IFN‐I–Dependent Feedback Control of pDC Egress
Working model of SLC44A2‐mediated maintenance of pDC homeostasis. This model illustrates two central mechanisms by which SLC44A2 regulates pDC homeostasis: (1) SLC44A2 limits IFN‐I production by exporting amino acids (T, N, Q), thereby preventing spontaneous pDC activation.
Ruiqun Chen +11 more
wiley +1 more source
The respiratory microbiome: dynamics from health to disease. [PDF]
Lin W, Sun Z, Chen J, Huang S.
europepmc +1 more source
Large‐scale UK Biobank analyses identify clinical and proteomic signatures for early prediction of valvular heart disease and its subtypes. Proteins add predictive value for VHD, AVS, and MVR, with outcome‐specific compact panels showing translational potential. Multi‐layer evidence highlights matrix remodeling, protease regulation, immune inflammation,
Zhihao Jiang +10 more
wiley +1 more source
Cannabinoid GPCRs, ectopic olfactory GPCRs and TRP channels: a prespecified baseline-edit-rescue framework for testing higher-order membrane-conditioned integration. [PDF]
Yarar E.
europepmc +1 more source
How to better engage the private sector in health service delivery in Africa. [PDF]
Appleford G +3 more
europepmc +1 more source
A DLN dataset was built to analyze MABS composition versus in vitro/in vivo osteogenesis and angiogenesis. An MLP neural network, taking BG morphological parameters as input, extracts bioactive features from these datasets. A rabbit tibial defect model then validates 4D‐printed MABS for adaptability and bone regeneration in critical defects.
Xiongjie Liang +12 more
wiley +1 more source
Proteoform medicine: characterizing and targeting protein forms in human disease. [PDF]
Korchak JA +4 more
europepmc +1 more source
Cataloging Rules in Japan and Anglo-American Cataloguing Rules : In the Past Century and Present
3 KJ00000049185 論文 ...
openaire
ABSTRACT Background Therapeutic resistance limits durable survival in advanced/metastatic renal cell carcinoma (RCC) treated with first‐line tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI). We sought to define key resistance drivers and actionable targets.
Jinchen Luo +16 more
wiley +1 more source

